MD3481846T2 - 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA - Google Patents
24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA Download PDFInfo
- Publication number
- MD3481846T2 MD3481846T2 MDE20190582T MDE20190582T MD3481846T2 MD 3481846 T2 MD3481846 T2 MD 3481846T2 MD E20190582 T MDE20190582 T MD E20190582T MD E20190582 T MDE20190582 T MD E20190582T MD 3481846 T2 MD3481846 T2 MD 3481846T2
- Authority
- MD
- Moldova
- Prior art keywords
- disorder
- compound
- disorders
- alkyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359532P | 2016-07-07 | 2016-07-07 | |
| PCT/US2017/041199 WO2018009867A1 (en) | 2016-07-07 | 2017-07-07 | Oxysterols and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3481846T2 true MD3481846T2 (ro) | 2021-11-30 |
Family
ID=59383635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20190582T MD3481846T2 (ro) | 2016-07-07 | 2017-07-07 | 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10781231B2 (enExample) |
| EP (2) | EP3481846B1 (enExample) |
| JP (2) | JP6966486B2 (enExample) |
| AU (3) | AU2017292870B2 (enExample) |
| CY (1) | CY1124631T1 (enExample) |
| DK (1) | DK3481846T3 (enExample) |
| ES (1) | ES2884071T3 (enExample) |
| HR (1) | HRP20211272T8 (enExample) |
| HU (1) | HUE055263T2 (enExample) |
| LT (1) | LT3481846T (enExample) |
| MA (1) | MA45598B1 (enExample) |
| MD (1) | MD3481846T2 (enExample) |
| PL (1) | PL3481846T3 (enExample) |
| PT (1) | PT3481846T (enExample) |
| RS (1) | RS62222B1 (enExample) |
| SI (1) | SI3481846T1 (enExample) |
| SM (1) | SMT202100468T1 (enExample) |
| TW (1) | TWI752976B (enExample) |
| WO (1) | WO2018009867A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150158903A1 (en) | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| LT2968369T (lt) | 2013-03-13 | 2018-12-27 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai ir jų panaudojimo būdai |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| MX376833B (es) | 2015-07-06 | 2025-03-07 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| RS62220B1 (sr) | 2015-07-06 | 2021-09-30 | Sage Therapeutics Inc | Oksisteroli i postupci njihovog korišćenja |
| CN114272249A (zh) | 2016-04-01 | 2022-04-05 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2017292870B2 (en) | 2016-07-07 | 2021-10-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3519422B1 (en) | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| KR20250054838A (ko) | 2016-10-18 | 2025-04-23 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| ES2952106T3 (es) | 2016-10-18 | 2023-10-27 | Sage Therapeutics Inc | Oxisteroles y procedimientos de utilización de los mismos |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| CN111777654B (zh) * | 2020-06-11 | 2021-08-10 | 浙江神洲药业有限公司 | 一种泼尼松的制备方法 |
| WO2022261510A1 (en) | 2021-06-11 | 2022-12-15 | Sage Therapeutics, Inc. | Neuroactive steroid for the treatment of alzheimer's disease |
| US20250064833A1 (en) | 2021-12-13 | 2025-02-27 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CN115057906B (zh) * | 2022-07-28 | 2022-12-02 | 中节能万润股份有限公司 | 利用去氢表雄酮合成胆固醇的方法 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2594323A (en) | 1948-07-22 | 1952-04-29 | Upjohn Co | 24-substituted delta 5-cholene-3, 24-diols |
| US2673206A (en) | 1950-06-07 | 1954-03-23 | Schering Corp | 25-ethinyl steroids |
| US3079385A (en) | 1961-01-24 | 1963-02-26 | Roussel Uclaf | Novel process of preparation of polyhydroxylated pregnanes |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| JPS5324071B2 (enExample) | 1974-04-30 | 1978-07-18 | ||
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| CH628907A5 (en) | 1975-10-10 | 1982-03-31 | Hoffmann La Roche | Process for the preparation of 24,25-dihydroxycholesterol derivatives |
| JPS5840960B2 (ja) | 1976-12-28 | 1983-09-08 | 帝人株式会社 | ヒドロキシコレステロ−ル立体異性体間の相互変換法 |
| US4183852A (en) | 1977-07-18 | 1980-01-15 | Kaiser Emil T | Process for preparing 25-hydroxycholesterol |
| JPS54163565A (en) | 1978-06-09 | 1979-12-26 | Teijin Ltd | 24*255epoxyy3beta * 266 dihydroxyychlestoo55ene or protected derivative of hydroxyl group thereof and production |
| US4174345A (en) | 1978-08-01 | 1979-11-13 | Kaiser Emil T | Synthesis of steroids |
| US4269777A (en) | 1979-05-21 | 1981-05-26 | Wisconsin Alumni Research Foundation | Isotopically labeled vitamin D derivatives and processes for preparing same |
| JPS5735597A (en) | 1980-08-13 | 1982-02-26 | Teijin Ltd | 25,26-epoxy-3beta,24-dihydroxycholest-5-ene or its hydroxyl- protected derivative and their preparation |
| JPS61254599A (ja) | 1985-05-07 | 1986-11-12 | Sumitomo Pharmaceut Co Ltd | コレステロ−ルのフツ素誘導体 |
| ATE45347T1 (de) | 1985-05-30 | 1989-08-15 | Taisho Pharmaceutical Co Ltd | Vitamin d3-derivate. |
| JPS62187485A (ja) | 1986-02-13 | 1987-08-15 | Teijin Ltd | ２４，２５−エポキシコレステロ−ル類の製造法 |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| AU698834B2 (en) | 1993-05-24 | 1998-11-12 | Purdue Pharma Ltd. | Methods and compositions for inducing sleep |
| IL110309A0 (en) | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| DE4338316A1 (de) | 1993-11-10 | 1995-05-11 | Jenapharm Gmbh | Neue Steroide mit radikophilen Substituenten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| NZ282939A (en) | 1994-02-14 | 1998-08-26 | Cocensys Inc | Androstanes and pregnanes for allosteric modulation of gaba receptors |
| TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| US5595996A (en) | 1994-10-25 | 1997-01-21 | Merck & Co., Inc. | 7-substituted 4-aza cholanic acid derivatives and their use |
| JPH08268917A (ja) | 1995-03-31 | 1996-10-15 | D D S Kenkyusho:Kk | 癌組織への移行性の高い制癌剤 |
| KR19990022323A (ko) | 1995-06-06 | 1999-03-25 | 씨. 랜 낸시 | 안드로스탄 및 프레그난 시리즈의 신경활성 스테로이드 |
| RU2182909C2 (ru) | 1995-06-23 | 2002-05-27 | Ново Нордиск А/С | Стероиды, способ регулирования мейоза |
| US6645953B2 (en) | 1995-06-23 | 2003-11-11 | Novo Nordisk A/S | Meiosis regulating compounds |
| US5888996A (en) * | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
| EP0840612A1 (en) * | 1995-07-24 | 1998-05-13 | Trustees Of Boston University | Inhibition of nmda receptor activity by pregnenolone sulfate derivatives |
| WO1997042215A1 (en) | 1996-05-06 | 1997-11-13 | Bionumerik Pharmaceuticals, Inc. | Process for preparing 27-hydroxy cholesterol and related derivatives |
| JPH09328498A (ja) | 1996-06-10 | 1997-12-22 | Teijin Ltd | ２４，２５−ジヒドロキシコレステロールの製造法およびその合成中間体 |
| DE19635525A1 (de) | 1996-08-20 | 1998-02-26 | Schering Ag | 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln |
| US6122371A (en) | 1997-07-22 | 2000-09-19 | Atwell; Ronald C. | Apparatus for protecting coin-operated telephones from vandalism and larceny |
| WO1999058497A1 (en) | 1998-05-11 | 1999-11-18 | Novo Nordisk A/S | Substituted guanidines and diaminonitroethenes, their preparation and use |
| IL139241A0 (en) | 1998-05-13 | 2001-11-25 | Novo Nordisk As | Meiosis regulating compounds |
| US8541600B2 (en) | 1998-11-24 | 2013-09-24 | Harbor Therapeutics, Inc. | 11-aza, 11-thia and 11-oxa sterol compounds and compositions |
| DE19917930A1 (de) | 1999-04-15 | 2000-10-19 | Schering Ag | Ent-Steroide als selektiv wirksame Estrogene |
| GB9910934D0 (en) | 1999-05-11 | 1999-07-14 | Res Inst Medicine Chem | Chemical compounds |
| CN1111167C (zh) | 1999-10-22 | 2003-06-11 | 中国科学院上海有机化学研究所 | 3β－羟基－5－胆烯酸酯类衍生物、合成方法及其用途 |
| CN1098273C (zh) | 1999-11-12 | 2003-01-08 | 中国科学院上海有机化学研究所 | 高立体选择性的合成24r,25－和24s,25－二羟基甾体化合物 |
| GB0000228D0 (en) | 2000-01-06 | 2000-03-01 | Phytopharm Plc | Fluoro substituted sapogenins and their use |
| GB0019290D0 (en) | 2000-08-04 | 2000-09-27 | Symphar Sa | Methods for inducing apolipoprotein E secretion |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| GB0107822D0 (en) | 2001-03-28 | 2001-05-23 | Phytopharm Plc | Sapogenin derivatives their synthesis and use methods based upon their use |
| US20070197484A1 (en) | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| EP1450816A4 (en) | 2001-11-08 | 2008-02-13 | Univ Chicago | METHOD OF TREATING DISORDERS RELATED TO HIGH CHOLESTEROL RATE |
| AU2002360489A1 (en) | 2001-12-07 | 2003-06-23 | The Regents Of The University Of California | Treatment for age-related macular degeneration |
| NZ547344A (en) | 2002-03-27 | 2007-11-30 | Phytopharm Plc | Therapeutic methods and uses of sapogenins and their derivatives |
| CN102727501A (zh) | 2002-03-27 | 2012-10-17 | 菲特法姆股份有限公司 | 皂角苷配基及其衍生物的用途 |
| US6933312B2 (en) | 2002-10-07 | 2005-08-23 | Agouron Pharmaceuticals, Inc. | Pyrazole derivatives |
| WO2004055201A2 (en) | 2002-12-13 | 2004-07-01 | Bayer Healthcare Ag | Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease |
| FR2850023B1 (fr) | 2003-01-17 | 2007-04-06 | Mapreg | Medicaments pour le systeme nerveux |
| GB0403889D0 (en) | 2004-02-21 | 2004-03-24 | Univ Edinburgh | Uses of er-beta modulators |
| WO2006037016A2 (en) | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| CA2643732C (en) | 2006-02-27 | 2012-08-21 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| GB0619860D0 (en) | 2006-10-06 | 2006-11-15 | Birkeland Innovasjon As | Treatment of insulin resistance and disorders associated therewith |
| WO2008057468A1 (en) | 2006-11-02 | 2008-05-15 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
| EP2170828B1 (en) | 2007-06-20 | 2012-11-21 | Auspex Pharmaceuticals, Inc. | Substituted n-aryl pyridinones as fibrotic inhibitors |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| CA2703497A1 (en) | 2007-11-06 | 2009-05-14 | N.V. Organon | A method of hormone suppression in humans |
| CA2707663C (en) | 2007-12-03 | 2017-05-30 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
| WO2009090063A1 (en) | 2008-01-16 | 2009-07-23 | Jado Technologies Gmbh | Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases |
| JP2011520815A (ja) | 2008-05-09 | 2011-07-21 | エモリー・ユニバーシテイ | 精神神経障害治療のためのｎｍｄａ受容体拮抗薬 |
| WO2010065709A2 (en) | 2008-12-03 | 2010-06-10 | Amin Khan | Hydroxamic acid derivatives, preparation and therapeutic uses thereof |
| US20120040916A1 (en) | 2008-12-22 | 2012-02-16 | Massachusetts Institute Of Technology | Molecular inhibitors of the wnt/beta-catenin pathway |
| US8822462B2 (en) | 2009-01-28 | 2014-09-02 | Emory University | Subunit selective NMDA receptor potentiators for the treatment of neurological conditions |
| EP2459581A4 (en) | 2009-07-29 | 2012-12-26 | Univ Chicago | LIVER X-RECEPTOR AGONISTS |
| WO2011028794A2 (en) | 2009-09-01 | 2011-03-10 | Lazarus Therapeutics, Inc. | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist |
| FR2953138B1 (fr) | 2009-12-02 | 2015-10-16 | Assist Publ Hopitaux Marseille | Composes aminosteroidiens pour une application topique locale pour la decolonisation cutaneo-muqueuse de staphylococcus aureus |
| WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
| KR101692275B1 (ko) | 2010-02-11 | 2017-01-04 | 노오쓰웨스턴 유니버시티 | ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도 |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US20120035156A1 (en) | 2010-08-09 | 2012-02-09 | Daniela Alberati | Combination of glyt1 compound with antipsychotics |
| US8969525B2 (en) | 2010-11-09 | 2015-03-03 | Enzo Life Sciences, Inc. | Hydroxycholesterol immunoassay |
| US20150031655A1 (en) | 2011-04-15 | 2015-01-29 | University Of North Dakota | Combination of liver x receptor modulator and estrogen receptor modulator for the treatment of age-related diseases |
| EP2714081A4 (en) | 2011-05-27 | 2015-09-09 | Cytocure Llc | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| US20150158903A1 (en) * | 2011-09-08 | 2015-06-11 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2738526T3 (es) | 2011-10-14 | 2020-01-23 | Sage Therapeutics Inc | Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos |
| WO2013163455A2 (en) | 2012-04-25 | 2013-10-31 | The Regents Of The University Of California | A drug screening platform for rett syndrome |
| US20140149272A1 (en) | 2012-08-17 | 2014-05-29 | Trueex Group Llc | Interoffice bank offered rate financial product and implementation |
| BR112015014397B1 (pt) | 2012-12-18 | 2021-02-02 | Washington University | composto, composição farmacêutica e uso de um composto |
| EP2948152A4 (en) | 2013-01-23 | 2016-12-14 | Sphaera Pharma Private Ltd | NOVEL COMPOUNDS OF 11-BETA HYDROXY-STEROIDS FOR USE IN MITOCHONDRIA BIOGENESIS AND DISEASES RELATED TO MITOCHONDRIA DYSFUNCTION OR ADDITIONAL |
| MX2015009773A (es) | 2013-01-29 | 2016-08-05 | Aptinyx Inc | Moduladores de receptores nmda de espiro-lactama y sus usos. |
| IL286970B2 (en) | 2013-03-13 | 2024-11-01 | Sage Therapeutics Inc | Neuroactive steroids and methods of use thereof |
| LT2968369T (lt) | 2013-03-13 | 2018-12-27 | Sage Therapeutics, Inc. | Neuroaktyvūs steroidai ir jų panaudojimo būdai |
| ES2970222T3 (es) | 2014-06-18 | 2024-05-27 | Sage Therapeutics Inc | Oxiesteroles y procedimientos de uso de los mismos |
| US10238664B2 (en) | 2014-07-09 | 2019-03-26 | Duke University | Compositions and methods for the repair of myelin |
| EP3204011A4 (en) | 2014-10-07 | 2018-06-20 | Sage Therapeutics, Inc. | Neuroactive compounds and methods of use thereof |
| RS62220B1 (sr) | 2015-07-06 | 2021-09-30 | Sage Therapeutics Inc | Oksisteroli i postupci njihovog korišćenja |
| MX376833B (es) | 2015-07-06 | 2025-03-07 | Sage Therapeutics Inc | Oxiesteroles y metodos de uso de los mismos. |
| MA42409A (fr) | 2015-07-06 | 2018-05-16 | Sage Therapeutics Inc | Oxystérols et leurs procédés d'utilisation |
| GB2557875A (en) | 2015-09-02 | 2018-07-04 | Univ Swansea | Diagnostic methods and kits |
| CN114272249A (zh) | 2016-04-01 | 2022-04-05 | 萨奇治疗股份有限公司 | 氧甾醇及其使用方法 |
| US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| AU2017292870B2 (en) | 2016-07-07 | 2021-10-07 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
| EP3519422B1 (en) | 2016-09-30 | 2022-08-31 | Sage Therapeutics, Inc. | C7 substituted oxysterols and these compounds for use as nmda modulators |
| KR20250054838A (ko) | 2016-10-18 | 2025-04-23 | 세이지 테라퓨틱스, 인크. | 옥시스테롤 및 그의 사용 방법 |
| ES2952106T3 (es) | 2016-10-18 | 2023-10-27 | Sage Therapeutics Inc | Oxisteroles y procedimientos de utilización de los mismos |
| JP7332478B2 (ja) | 2017-03-15 | 2023-08-23 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子製剤 |
| CN110945006A (zh) | 2017-06-23 | 2020-03-31 | 英特塞普特医药品公司 | 用于制备胆汁酸衍生物的方法和中间体 |
| SG10202110563YA (en) | 2017-11-10 | 2021-11-29 | Marinus Pharmaceuticals Inc | Ganaxolone for use in treating genetic epileptic disoders |
-
2017
- 2017-07-07 AU AU2017292870A patent/AU2017292870B2/en active Active
- 2017-07-07 RS RS20211006A patent/RS62222B1/sr unknown
- 2017-07-07 SI SI201730870T patent/SI3481846T1/sl unknown
- 2017-07-07 PL PL17742595T patent/PL3481846T3/pl unknown
- 2017-07-07 EP EP17742595.6A patent/EP3481846B1/en active Active
- 2017-07-07 PT PT177425956T patent/PT3481846T/pt unknown
- 2017-07-07 MA MA45598A patent/MA45598B1/fr unknown
- 2017-07-07 EP EP21172788.8A patent/EP3919502A1/en not_active Withdrawn
- 2017-07-07 LT LTEP17742595.6T patent/LT3481846T/lt unknown
- 2017-07-07 TW TW106122956A patent/TWI752976B/zh active
- 2017-07-07 ES ES17742595T patent/ES2884071T3/es active Active
- 2017-07-07 WO PCT/US2017/041199 patent/WO2018009867A1/en not_active Ceased
- 2017-07-07 DK DK17742595.6T patent/DK3481846T3/da active
- 2017-07-07 MD MDE20190582T patent/MD3481846T2/ro unknown
- 2017-07-07 US US16/315,250 patent/US10781231B2/en active Active
- 2017-07-07 HR HRP20211272TT patent/HRP20211272T8/hr unknown
- 2017-07-07 SM SM20210468T patent/SMT202100468T1/it unknown
- 2017-07-07 JP JP2018568810A patent/JP6966486B2/ja active Active
- 2017-07-07 HU HUE17742595A patent/HUE055263T2/hu unknown
-
2020
- 2020-07-30 US US16/943,649 patent/US11279730B2/en active Active
-
2021
- 2021-08-06 CY CY20211100708T patent/CY1124631T1/el unknown
- 2021-08-16 JP JP2021132225A patent/JP2021175761A/ja not_active Withdrawn
- 2021-09-17 AU AU2021232833A patent/AU2021232833B2/en active Active
-
2023
- 2023-12-28 AU AU2023286014A patent/AU2023286014B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023286014B2 (en) | Oxysterols and methods of use thereof | |
| US12331070B2 (en) | C7 substituted oxysterols and methods of use thereof | |
| EP3529256B1 (en) | Oxysterols and methods of use thereof | |
| HK40064932A (en) | 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions | |
| CA3029900C (en) | Oxysterols and methods of use thereof | |
| HK40006669B (en) | 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions | |
| HK40083913A (en) | Oxysterols and methods of use thereof | |
| HK40004830A (en) | C7 substituted oxysterols and these compounds for use as nmda modulators | |
| HK40004830B (en) | C7 substituted oxysterols and these compounds for use as nmda modulators | |
| HK40006309A (en) | Oxysterols and methods of use thereof | |
| HK40006309B (en) | Oxysterols and methods of use thereof |